Research Papers:
TIPE2 suppresses angiogenesis and non-small cell lung cancer (NSCLC) invasiveness via inhibiting Rac1 activation and VEGF expression
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2519 views | HTML 2990 views | ?
Abstract
Zequn Li1, Chun Guo1, Xianglan Liu1, Chengjun Zhou2, Faliang Zhu1, Xiaoyan Wang1, Qun Wang1, Yongyu Shi1, Jianing Wang1, Wei Zhao1, Lining Zhang1
1Department of Immunology, Shandong University School of Medicine, Jinan, China
2Department of Pathology, The Second Hospital of Shandong University, Jinan, China
Correspondence to:
Lining Zhang, email: [email protected]
Keywords: TIPE2, NSCLC, angiogenesis, invasiveness, Rac1
Received: September 22, 2015 Accepted: August 08, 2016 Published: August 19, 2016
ABSTRACT
Non-small cell lung cancer (NSCLC) is one of the leading causes of all cancer-related deaths worldwide. Despite extensive efforts to improve the diagnosis and treatment of this neoplasm, limited progress has been made. Tumor necrosis factor (TNF)-alpha-induced protein 8-like 2 (TIPE2 or TNFAIP8L2) is a newly introduced negative immune regulator, which also controls tumorigenesis. However, the role of TIPE2 in angiogenesis is unknown. In the present study, we investigated the expression and roles of TIPE2 in NSCLC. TIPE2 upregulation in human NSCLC tissues was negatively associated with the primary tumor size, lymph node metastasis, and advanced clinical stage, which can be used to predict lymph node metastasis. Moreover, overexpression of TIPE2 not only inhibited the colony formation, migration, and invasion of NSCLC cells but also indirectly suppressed the proliferation, migration, and tube formation of vascular endothelial cells. Furthermore, TIPE2 suppressed tumor invasiveness and angiogenesis via inhibiting the activation of Rac1 and subsequently weakening its downstream effects, including F-actin polymerization and VEGF expression. Collectively, these results indicate that TIPE2 plays a key role in NSCLC metastasis, suggesting that forced TIPE2 expression might be a novel strategy for the treatment of NSCLC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 11406